Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes

Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes

Show other versions (3)

Bibliographic Details
Main Authors:	Rebecca C. Coll, Luke A. J. O'Neill
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586581/?tool=EBI

Similar Items

Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
by: Rebecca C. Coll, et al.
Published: (2013-01-01)

Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes.
by: Rebecca C. Coll, et al.
Published: (2013-01-01)

Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes.
by: Rebecca C. Coll, et al.
Published: (2013-01-01)

The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes.
by: Rebecca C Coll, et al.
Published: (2011-01-01)

Tyrosine Dephosphorylation of ASC Modulates the Activation of the NLRP3 and AIM2 Inflammasomes
by: Bezaleel Mambwe, et al.
Published: (2019-07-01)

Artemisia Extract Suppresses NLRP3 and AIM2 Inflammasome Activation by Inhibition of ASC Phosphorylation
by: Su-Bin Kwak, et al.
Published: (2018-01-01)

Prion pathogenesis in the absence of NLRP3/ASC inflammasomes.
by: Mario Nuvolone, et al.
Published: (2015-01-01)

Suppression of Glucagon-Like Peptide-1 Release by Inhibition of Intestinal NLRP3 Inflammasome Activation in Asc–/– and Nlrp3–/– Mice
by: Yu Chen, et al.
Published: (2019-10-01)

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
by: Lieselotte Vande Walle, et al.
Published: (2019-09-01)

Involvement of Asc and Nlrp3 inflammasomes in the testes following spinal cord injury
by: Ramezanikhah Hajar, et al.
Published: (2020-04-01)

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
by: Lieselotte Vande Walle, et al.
Published: (2019-10-01)

Adenovirus VA RNAI Blocks ASC Oligomerization and Inhibits NLRP3 Inflammasome Activation
by: Mahmoud Darweesh, et al.
Published: (2019-11-01)

The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis: Review
by: Magdalena Ciążyńska, et al.
Published: (2021-05-01)

Structure, Activation and Regulation of NLRP3 and AIM2 Inflammasomes
by: Meenakshi Sharma, et al.
Published: (2021-01-01)

The Supportive Role of NSC328382, a P2X7R Antagonist, in Enhancing the Inhibitory Effect of CRID3 on NLRP3 Inflammasome Activation in Rats with Dextran Sodium Sulfate-Induced Colitis
by: Saber S, et al.
Published: (2021-07-01)

A Yersinia effector with enhanced inhibitory activity on the NF-κB pathway activates the NLRP3/ASC/caspase-1 inflammasome in macrophages.
by: Ying Zheng, et al.
Published: (2011-04-01)

Transcriptional Suppression of the NLRP3 Inflammasome and Cytokine Release in Primary Macrophages by Low-Dose Anthracyclines
by: Nilay Köse-Vogel, et al.
Published: (2019-12-01)

Role of HIF-1α in NLRP3 and AIM2 inﬂammasome activation
by: Yi-Syuan Li, et al.
Published: (2016)

Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation
by: Tali Lang, et al.
Published: (2018-06-01)

ATP release and purinergic signaling in NLRP3 inflammasome activation
by: Isabelle eCOUILLIN, et al.
Published: (2013-01-01)

Cytokine Secretion and Pyroptosis of Thyroid Follicular Cells Mediated by Enhanced NLRP3, NLRP1, NLRC4, and AIM2 Inflammasomes Are Associated With Autoimmune Thyroiditis
by: Qingling Guo, et al.
Published: (2018-06-01)

Anti-GBM glomerulonephritis involves IL-1 but is independent of NLRP3/ASC inflammasome-mediated activation of caspase-1.
by: Julia Lichtnekert, et al.
Published: (2011-01-01)

PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation
by: Min Xie, et al.
Published: (2016-10-01)

Shikonin Suppresses NLRP3 and AIM2 Inflammasomes by Direct Inhibition of Caspase-1.
by: Jernej Zorman, et al.
Published: (2016-01-01)

Compliant Substrates Enhance Macrophage Cytokine Release and NLRP3 Inflammasome Formation During Their Pro-Inflammatory Response
by: Joan-Carles Escolano, et al.
Published: (2021-03-01)

Inhibiting the NLRP3 Inflammasome
by: Lina Y. El-Sharkawy, et al.
Published: (2020-11-01)

Inhibitory Effect and Mechanism of Arctium lappa Extract on NLRP3 Inflammasome Activation
by: Young-Kyu Kim, et al.
Published: (2018-01-01)

Herpes simplex virus type 1 inflammasome activation in proinflammatory human macrophages is dependent on NLRP3, ASC, and caspase-1.
by: Andrew H Karaba, et al.
Published: (2020-01-01)

Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4.
by: Edel A McNeela, et al.
Published: (2010-11-01)

Die Rolle des AIM2 und NLRP3 Inflammasoms in Kolonadenom- und Kolonkarzinomzelllinien
by: Peschke, Franziska
Published: (2015)

Correction: Shikonin Suppresses NLRP3 and AIM2 Inflammasomes by Direct Inhibition of Caspase-1.
by: Jernej Zorman, et al.
Published: (2016-01-01)

miR-34 expression levels in relation to NLRP3 inflammasome activation in THP1-ASC-GFP cells : Pilot study
by: Smith, Alyssa
Published: (2020)

Lactobacillus rhamnosus GR-1 Ameliorates Escherichia coli-Induced Activation of NLRP3 and NLRC4 Inflammasomes With Differential Requirement for ASC
by: Qiong Wu, et al.
Published: (2018-07-01)

Vitamin D and the NLRP3 Inflammasome
by: Matthew Tunbridge, et al.
Published: (2020-11-01)

Role of the NLRP3 Inflammasome in Preeclampsia
by: Koumei Shirasuna, et al.
Published: (2020-02-01)

Regulation of NLRP3 Inflammasome by Phosphorylation
by: Nan Song, et al.
Published: (2018-10-01)

Role of the NLRP3 inflammasome in cancer
by: Maryam Moossavi, et al.
Published: (2018-11-01)

Pharmacological Inhibitors of the NLRP3 Inflammasome
by: Ayesha Zahid, et al.
Published: (2019-10-01)

Spotlight on the NLRP3 inflammasome pathway
by: Groslambert M, et al.
Published: (2018-09-01)

NLRP3 Inflammasome and Inflammatory Diseases
by: Zheng Wang, et al.
Published: (2020-01-01)